Trials / Active Not Recruiting
Active Not RecruitingNCT06684366
Chronic Coronary Syndrome Real Practice and Guidelines
Chronic Coronary Syndrome...real Practice and Guidelines...A Single Center Registery
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate Adherence to the 2019 ESC Guidelines and standard care protocols for managing patients with the chronic coronary syndrome within the center
Detailed description
Coronary artery disease (CAD) refers to the presence of atherosclerotic plaques in the coronary arteries, Which can be non-obstructive or obstructive. It represents a major cause of morbidity, mortality, Hospitalization and health expenditure. The most recent European Guidelines for the diagnosis and management of CCS delineate six common CCS scenarios: patients with suspected CAD and stable angina symptoms and/or dyspnea; patients with new onset of heart failure or left ventricular dysfunction and suspected CAD; asymptomatic and symptomatic patients with stabilized symptoms within one year after an acute coronary syndrome, or patients with recent revascularisation; asymptomatic and symptomatic patients beyond one year after initial diagnosis or revascularisation; Patients with angina and suspected vasospastic or microvascular disease; Asymptomatic subjects in whom CAD is detected at screening. Although these scenarios are heterogeneous, they are associated with an increased risk of acute events, and the stability of CCS patients over time depends on prompt diagnosis, optimal treatment and secondary prevention strategies, including Lifestyle modifications, and pharmacotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Statins (atorvastatin or simvastatin) | A resting transthoracic echocardiogram Non-invasive functional imaging for myocardial ischemia or coronary computed tomography angiography (CCTA) is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone |
Timeline
- Start date
- 2024-10-22
- Primary completion
- 2025-10-22
- Completion
- 2025-10-22
- First posted
- 2024-11-12
- Last updated
- 2024-11-12
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06684366. Inclusion in this directory is not an endorsement.